Ovarian cancer is the fourth most common cause of cancer-related death in women in the developed world, and one of the most heritable cancers. One of the most significant risk factors for epithelial ovarian cancer (EOC) is a family history of breast and/or ovarian cancer. Combined risk factors can be used in models to stratify risk of EOC, and aid in decisions regarding risk-reduction strategies. Germline pathogenic variants in EOC susceptibility genes including those involved in homologous recombination and mismatch repair pathways are present in approximately 22% to 25% of EOC. These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) thought to explain an additional 6.4% of the familial risk of ovarian cancer, with 34 susceptibility loci identified to date. However, an unknown proportion of the genetic component of EOC risk remains unexplained.
| INTRODUCTION
With knowledge of risk of ovarian cancer rapidly increasing, physicians are better equipped to advise women and their families than ever before regarding their individual risk. Due to public advertisements of genetic home testing, the "Angelina Jolie effect," 1 general media coverage of cancer genetics and widening access to the internet and social media, the general public are becoming increasingly aware of the use of genetic testing in assessing cancer risk. However, risk assessment of ovarian cancer at the individual level is still relatively imprecise, and predominately based on environmental, familial and hormonal factors. Much is still also not known about the influence of individual genes on risk of ovarian cancer especially the contribution not explained by the BRCA1 and BRCA2 genes and the role of single nucleotide polymorphisms. Further research is needed to identify additional variants involved and to improve the accuracy of multifactorial risk assessment in an individual's risk of ovarian cancer to enable physicians to advise patients optimally regarding risk reduction strategies.
| Ovarian cancer
Ovarian cancer is the fifth most common cause of cancer in women in the developed world and fourth most common cause of cancerrelated death. 2, 3 It carries an estimated lifetime risk of one in 54 to 75, and one in 100 of ovarian cancer-related mortality. 3, 4 The agestandardized incidence is approximately 9.4 per 100 000 in developed regions and 5 per 100 000 in less developed areas. 5 Frequently diagnosed at an advanced stage, symptoms can be vague and sometimes misattributed to irritable bowel syndrome. 6 The median age at diagnosis is 63 years. 7 Prognosis of invasive epithelial ovarian cancer is influenced by age, International Federation of Gynaecological Oncologists (FIGO) stage, performance status, volume of residual disease after initial debulking surgery and BRCA status. 6, 8 Median progression-free survival (PFS) for patients with advanced ovarian cancer is approximately 18 months, and overall survival (OS) for all ovarian cancer 40% to 50% at 10 years. 6 Epithelial ovarian cancer (EOC) comprises 60% of ovarian tumours, and is further classified into benign, borderline and malignant. High grade serous ovarian cancer (HGSOC) comprises 70% to 80% of malignant EOC, and usually presents at a late stage with disseminated disease. 9 Originally thought to originate from the ovarian surface, these are now thought to originate predominantly from fallopian tube epithelium. 9 Pathogenic somatic variants have been found in TP53 in almost 100% of HGSOC tumours, and also in FAT3, CSMD3, NF1, RAD51C, RAD51D, BRIP1, RB1, GABRA6, CDK12 and well-known tumour suppressor genes BRCA1 and BRCA2. Notch and FOXM1 signalling pathways are also implicated. [10] [11] [12] [13] The genomic instability present in HGSOC promotes the development of further variants, increases genetic diversity and development of genetically distinct subclones within a tumour. 14 Genomic instability can be associated with treatment resistance and poor prognosis if subclones develop genomic characteristics that benefit tumour survival. However, conversely, higher levels of genomic instability can enable the acquisition of pathogenic variants with a selective disadvantage, by limiting tumour growth or increasing response to chemotherapy. 14 In HGSOC, higher levels of genomic instability are associated with higher platinum-based chemotherapy and poly ADP ribose polymerase (PARP) inhibitor response rates, and improved survival outcomes.
14 Low grade serous ovarian cancer makes up 10% of serous ovarian cancers. It behaves in a more indolent fashion than HGSOC, and has low response rates to chemotherapy and hormonal agents. 6 They are commonly diagnosed at an advanced stage and OS is poor. 9, 15 Women with low grade serous ovarian cancer rarely have a family history of breast and/or ovarian cancer. 16 In contrast to HGSOC, pathogenic somatic variants have been found in KRAS, NRAS, BRAF, ERBB2
and PI3KCA oncogenes. 6 The mitogen-activated protein kinase There is a 3-fold increase in risk of developing ovarian cancer in women with a first-degree relative with ovarian cancer. 23 The relative risk (RR) is higher for first-degree relatives diagnosed <50 years than for those >50 (4.7 vs 2.5, P = .0052). Having serous ovarian cancer carries with it a higher RR for first-degree relatives than non-serous ovarian cancer (RR = 3.6 vs 2.3, P = .023). 24 Hormonal and reproductive factors are the most significant other risk factors. A higher lifetime number of menstrual cycles is associated with a higher risk of EOC, 25 suggesting that ovulation is involved in ovarian carcinogenesis. Factors that reduce ovulation, including pregnancy, breastfeeding and the oral contraceptive pill, are protective and nulliparity associated with higher risk. [26] [27] [28] Hormone replacement therapy (HRT) carries a modest but persistent risk, 29 as do increased height, weight and body mass index. 30, 31 There is no significant association with diet or alcohol. [32] [33] [34] Tobacco smoking is associated only with MOC. 35 Endometriosis is associated with 15% to 20% of clear cell and endometrioid ovarian cancer, and carries up to a 3-fold risk.
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| Epithelial ovarian cancer susceptibility genes
Frequencies of pathogenic variants in high, moderate and low penetrance (commonly defined as ≥10%, 5%-9% and ≤ 4%) EOC susceptibility genes in the unselected ovarian cancer population and HBOC families vary with population number, characteristics, geography, cancer subtype and technique used in analysis. These frequencies are summarized in Table S1 , cancer-associated risks in Table S2 and comparisons between frequency and risk between the general population, unselected EOC and HBOC families in Table 1 . 
| Homologous recombination genes

| BRCA genes, BRCAness and methylation
Identified in 1990 and mapped to chromosome 17q21, BRCA1 plays essential roles in DNA damage repair, cell-cycle arrest, transcriptional activation, chromatin remodelling, apoptosis and genetic stability. 40, 44 In cancer patients, pathogenic BRCA1 variants most commonly occur 24 Since the discovery of BRCA1 and BRCA2, the phenotype "BRCAness": patients with genomic instability, serous histology, high response rates to platinum-based chemotherapy, long treatment-free intervals, good OS but without a detected BRCA variant, has been described. 43, 54 Attempts to identify BRCAness more distinctly with molecular classification are ongoing. 40 Being able to identify this patient group reliably could allow management to be tailored in a more targeted manner and allow greater a number of patients to access treatments currently restricted to those with a BRCA variant.
Epigenetic mechanisms of BRCA inactivation such as promoter methylation causing transcriptional silencing of cancer-associated genes have also been identified. 40, 55 Methylation in cancer has been found to occur in the cytosine residues in CpG dinucleotides which occur in the promoters of many genes. Up to one-third of ovarian cancers show dysfunctional methylation of the BRCA1 promoter 40 to the extent that in most cases BRCA1 expression is undetectable. An example is two HBOC families recently described to have a dominantly inherited 5' UTR variant (c.-107 T > A), associated with epigenetic BRCA1 silencing caused by promoter hypermethylation. 56 The clinical features of the affected women were consistent with the BRCA1 phenotype.
| Other homologous recombination genes
The gene, RAD51C, isolated in 1998 and localized to chromosome 17q23, 57 is one of the five RAD51 paralogs. Together, their protein products form the BCDX2 complex responsible for RAD51 recruitment and stabilization at DNA damage sites. 58 Pathogenic variants have been found in a functional domain in the C-terminus of the protein, an area important in forming RAD51B-RAD51C-RAD51D-XRCC2 and RAD51C-XRCC2 complexes, and therefore, in doublestrand DNA repair, demonstrating the influence of variants on HR. 59 Affected women may develop EOC up to 6 years earlier than the general population. 58, 60, 61 The risk is higher for serous ovarian cancer (OR = 7.4, 95% CI 1.6-35.0) compared to all ovarian cancer subtypes (OR = 5.2, 95% CI 1.1-24.0, P = .035) and the cumulative lifetime risk is 5% to 11%.
11,59
Its paralog RAD51D, also isolated in 1998, is localized to 17q11. 62 It recruits RAD51 to DNA damage sites and is vital during embryonic development. 63, 64 Pathogenic variants have been found in the Cterminal region involved in binding to RAD51C. 59 Short interfering
RNAi reagents targeting RAD51D have been observed to cause sensitivity to the PARP inhibitor, olaparib, similar to that seen by BRCA2
silencing. 12 This suggests that PARP inhibitors could be used in patients with RAD51D variants. Variants most commonly occur in HGSOC 59 and are estimated to confer a 6-fold increase in ovarian cancer risk, equating to approximately 10% cumulative risk by age 80. 12 Affected women may develop EOC up to 9 years earlier than the general population. 61 The gene PALB2, was discovered in 2006. PALB2 protein localizes with BRCA2 in nuclear foci, promoting localization, stability and enabling recombinational repair and checkpoint functions. 65 It also directly affects RAD51 function, promoting RAD51-mediated D-loop formation and DNA binding. 66 Although early studies did not confirm a significant increase in EOC risk it now looks likely that this was due to studies being underpowered, and cumulative lifetime risk of EOC is not known. Affected women may develop EOC up to 7 years earlier than the general population. 67 The protein BRIP1 interacts with BRCA1 through BRCT repeats at the c-terminal end of BRCA1 and is required for normal repair of double-strand DNA breaks. 68 Pathogenic variants in BRIP1 are predicted to truncate the protein before this BRCA1 binding domain. 13 Pathogenic variants in BRIP1 increase cell sensitivity to DNA-crosslinking agents 69 making patients with these variants more likely to be sensitive to platinum-based chemotherapy. An Icelandic study found the frameshift deletion c.2040_204insTT to be associated with increased risk of ovarian cancer (OR = 8.1, 95% CI 4.7-13.9, P = 2.8 x 10
) and average four years poorer OS. 70 Pathogenic variant carriers develop EOC at the same age as in the general population, and have an estimated 5.8% cumulative lifetime risk.
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Other low-risk HR genes for which only weak or insignificant associations have been found with EOC include ataxia telangiectasia (ATM), checkpoint kinase 2 (CHEK2) and nibrin (NBN) 81, 82 and MSH6 carriers (1%-13%).
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The prevalence of MMR-deficiency or microsatellite instability (MSI) in familial ovarian cancer has been estimated between 10% and 20%. 76, 84 Loss of MMR expression is more commonly found in nonserous ovarian cancer, particularly endometrioid and clear cell carcinomas. 85 Mean age at diagnosis in women with pathogenic germline MMR variants is 9 to 13 years earlier than the general population and cumulative lifetime risk of ovarian cancer has been reported as low as 3.7% (1.4%-13%). 86 Prognosis is affected by MMR variants. PFS is longer for MMR-deficient women compared to MMR-low and MMRproficient ovarian cancer (P = .0046). They are also more likely to be diagnosed at an earlier stage (P = .0041). 87 Ten-year ovarian cancerspecific survival has been found to be 80.6% in one series of MMR pathogenic variant carriers with ovarian cancer. 88 High mRNA expression of MSH6, MLH1, and PMS2 is associated with a significantly improved OS. 89 It has been suggested these patients could be good candidates for checkpoint inhibitors. 87 
| TP53
The crucial role of TP53 is exemplified by Li-Fraumeni syndrome, a disorder with close to 100% cancer incidence by age 70 90 ; the median age of ovarian cancer in these patients is 39.5 years. 91 Variants have been associated with ovarian cancer risk (OR = 18.50, 95% CI 2.56-808.1). 92 However, numerous studies have not found germline TP53 variants to be significantly associated with ovarian cancer or to affect risk.
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| Other syndromic associations
A number of other syndromic associations with ovarian cancer have been reported, such as with Peutz-Jeghers disease, although this association is not with EOC. 97 Another probably false association that has been frequently quoted is with Gorlin syndrome, an autosomal dominant condition associated with increased risk of childhood-onset brain tumours. 98 The latter may well be linked to transformation of benign ovarian fibromas to fibrosarcoma due to childhood spinal irradiation to treat medulloblastoma. 99 
| Interventions for women carrying a pathogenic variant
When a pathogenic variant is identified, it is essential that affected women are offered risk-reduction interventions and cascade testing be offered to relatives. Uptake of cascade testing in this situation has been noted to be relatively low, estimated at 15% to 57% in one systematic review 100 and genetic testing in eligible women with ovarian cancer also low. 130 The PRS has been further developed in combination with non-genetic risk factors and mammographic breast density. 131 The question of whether a polygenic score can be applied to ovarian cancer was speculatively addressed by Jervis et al in 2014 using an 11-SNP panel. 24 The familial RR increased with increasing PRS; however, this was not statistically significant. The RRs for relatives of probands in the highest quartile (RR 2.61, 95% CI 1.61-4.24) were also estimated to be lower than for those in the 25th to 75th quartiles (RR 3.83, 95% CI 2.56-5.73 for 50th-75th quartile). It was proposed that this was due to the small number of SNPs used.
There are limitations to PRSs and currently there is no consensus among clinicians of their utility. Models use varying SNPs, not always including the most significant germline pathogenic variants, and GWAS often include individuals from European ancestry, limiting the predictive ability of a PRS in non-European ancestry women.
| CONCLUSION
The heritability of ovarian cancer has not been completely explained.
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